Theravance Biopharma

Country

Ownership: -

Employees: 99

Market Cap: -

Website

Introduction: Theravance Biopharma, Inc. is a biopharmaceutical company, which engages in the discovery, research, development, and commercialization of respiratory medicines. It operates through the U.S. and Europe geographical segments. Its products include telavancin under the VIBATIV brand, revefenacin under the TD 4208 brand, and neprilysin. The company was founded in July 2013 and is headquartered in George Town, Cayman Islands.

Clinical Trials

Phase 3 Efficacy and Durability of Ampreloxetine for the Treatment of Symptomatic NOH in Participants with Multiple System Atrophy

Phase 3

Recruiting

Conditions: MSA - Multiple System Atrophy
Symptomatic Neurogenic Orthostatic Hypotension

Interventions: Drug: Ampreloxetine
Drug: Placebo

First Posted Date: 2023-01-25

Last Posted Date: 2024-12-27

Lead Sponsor: Theravance Biopharma

Target Recruit Count: 102

Registration Number: NCT05696717

Locations: 🇦🇷
Hospital Británico de Buenos Aires, Caba, Argentina
🇺🇸
Neurostudies, Inc, Port Charlotte, Florida, United States
🇺🇸
Movement Disorders Center of Arizona, Scottsdale, Arizona, United States

and more 66 locations

Phase 4 COPD and Suboptimal Inspiratory Flow Rate

Phase 4

Completed

Conditions: Chronic Obstructive Pulmonary Disease

Interventions: Drug: Revefenacin
Drug: Tiotropium
Drug: Revefenacin Placebo
Drug: Tiotropium Placebo

First Posted Date: 2021-12-21

Last Posted Date: 2024-12-20

Lead Sponsor: Theravance Biopharma

Target Recruit Count: 404

Registration Number: NCT05165485

Locations: 🇺🇸
Theravance Biopharma Investigational Site site 2, Clearwater, Florida, United States
🇺🇸
Theravance Biopharma Investigational Site, Cudahy, Wisconsin, United States
🇺🇸
Theravance Biopharma Investigational Site #2, Spartanburg, South Carolina, United States

TD-0903 Pharmacokinetics Study in Healthy Participants With Supplemental Oxygenation

Phase 1

Completed

Conditions: Acute Lung Injury (ALI) Due to Coronavirus Disease-2019 (COVID-19)

Interventions: Drug: Nezulcitinib (TD-0903) Dose A
Drug: Nezulcitinib (TD-0903) Dose B

First Posted Date: 2021-10-25

Last Posted Date: 2021-12-10

Lead Sponsor: Theravance Biopharma

Target Recruit Count: 14

Registration Number: NCT05091723

Locations: 🇺🇸
Theravance Biopharma Investigational Site, Cypress, California, United States

Thorough QT Study to Evaluate Ampreloxetine in Healthy Subjects

Phase 1

Completed

Conditions: Symptomatic Neurogenic Orthostatic Hypertension
nOH

Interventions: Drug: Ampreloxetine Placebo
Drug: Ampreloxetine <Dose A>
Drug: Moxifloxacin
Drug: Ampreloxetine <Dose B>
Drug: Moxifloxacin Placebo

First Posted Date: 2020-12-30

Last Posted Date: 2021-04-20

Lead Sponsor: Theravance Biopharma

Target Recruit Count: 72

Registration Number: NCT04688632

Locations: 🇺🇸
Theravance Biopharma Investigational Site, Tempe, Arizona, United States

Comparison of Viral Particle Dispersion Following Administration of an MDI or Nebulizer in Subjects With COVID-19

Completed

Conditions: COVID-19

Interventions: Drug: albuterol sulfate (MDI)
Drug: albuterol sulfate (nebulizer)

First Posted Date: 2020-12-23

Last Posted Date: 2022-01-28

Lead Sponsor: Theravance Biopharma

Target Recruit Count: 14

Registration Number: NCT04681079

Locations: 🇺🇸
Theravance Biopharma Investigational Site, Kansas City, Kansas, United States

TD-1058 First-In-Human Study in Healthy Subjects and Subjects With Idiopathic Pulmonary Fibrosis

Phase 1

Terminated

Conditions: Idiopathic Pulmonary Fibrosis (IPF)

Interventions: Drug: TD-1058
Drug: Placebo

First Posted Date: 2020-10-19

Last Posted Date: 2022-02-23

Lead Sponsor: Theravance Biopharma

Target Recruit Count: 72

Registration Number: NCT04589260

Locations: 🇬🇧
Theravance Biopharma Investigational Site, Manchester, United Kingdom

Single Dose Bioavailability and Ethnobridging PK Study in Healthy Subjects

Phase 1

Completed

Conditions: Bowel Diseases, Inflammatory
Intestinal Disorder

Interventions: Drug: TD-1473 [Tablet A]
Drug: TD-1473 [Tablet B]

First Posted Date: 2020-10-14

Last Posted Date: 2021-04-09

Lead Sponsor: Theravance Biopharma

Target Recruit Count: 58

Registration Number: NCT04587713

Locations: 🇺🇸
Theravance Biopharma Investigational Site, Lincoln, Nebraska, United States

TD-0903 for ALI Associated With COVID-19

Phase 2

Completed

Conditions: Acute Lung Injury (ALI) Associated With COVID-19
Lung Inflammation Associated With COVID-19

Interventions: Drug: TD-0903
Drug: Placebo

First Posted Date: 2020-05-27

Last Posted Date: 2022-03-17

Lead Sponsor: Theravance Biopharma

Target Recruit Count: 235

Registration Number: NCT04402866

Locations: 🇬🇧
Theravance Biopharma Investigational Site, Manchester, United Kingdom
🇺🇸
Theravance Biopharma, Hyde Park, New York, United States

First in Human SAD and MAD Study of Inhaled TD-0903, a Potential Treatment for ALI Associated With COVID-19

Phase 1

Completed

Conditions: Inflammatory Lung Conditions Associated With COVID-19
Acute Lung Injury (ALI) Associated With COVID-19

Interventions: Drug: Placebo
Drug: TD-0903

First Posted Date: 2020-04-17

Last Posted Date: 2021-07-01

Lead Sponsor: Theravance Biopharma

Target Recruit Count: 54

Registration Number: NCT04350736

Locations: 🇬🇧
Theravance Biopharma Investigational Site, Manchester, United Kingdom

Effect of Hepatic Impairment on the Pharmacokinetics of a Single Dose of TD-9855

Phase 1

Completed

Conditions: Symptomatic Neurogenic Orthostatic Hypertension
nOH

Interventions: Drug: Ampreloxetine

First Posted Date: 2019-12-16

Last Posted Date: 2021-09-08

Lead Sponsor: Theravance Biopharma

Target Recruit Count: 31

Registration Number: NCT04200573

Locations: 🇺🇸
Theravance Biopharma Investigational Site, Orlando, Florida, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy